author-photo

Pilar Lim

Janssen Pharmaceutica
Johnson & Johnson Pharmaceutical Research and Development

72

Papers

3689

Citations

Citation Trend

Filter By

Papers (72) Sort By

JournalConferenceOthers

A randomized, double-blind, multicenter, noninferiority study comparing paliperidone palmitate 6-month versus the 3-month long-acting injectable in patients with schizophrenia.

2021 The International Journal of Neuropsychopharmacology
Show All
- Source
- Cite
- Save
Citations (0)
Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies.

2021 CNS Drugs
Show All
- Source
- Cite
- Save
Citations (1)
Comparison of Long-Term Efficacy and Safety of Esketamine Nasal Spray Plus Oral Antidepressant in Younger Versus Older Patients With Treatment-Resistant Depression: Post-Hoc Analysis of SUSTAIN-2, a Long-Term Open-Label Phase 3 Safety and Efficacy Study.

2021 American Journal of Geriatric Psychiatry
Show All
- Source
- Cite
- Save
Citations (0)
Relationship Between the Short-Form 12 (SF-12) and Schizophrenia Symptom Rating Scales in a Randomized Controlled Clinical Trial of Paliperidone Palmitate 3 Monthly Formulation

2021 Biological Psychiatry
Show All
- Source
- Cite
- Save
Citations (0)
Post hoc analyses of an open-label long-term study of esketamine nasal spray plus an oral antidepressant comparing results in older versus younger adults with treatment-resistant depression

2021 American Journal of Geriatric Psychiatry
Show All
- Source
- Cite
- Save
Citations (1)
Continual reassessment method with regularization in phase I clinical trials.

2020 Journal of Biopharmaceutical Statistics
Show All
- Source
- Cite
- Save
Citations (0)
Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I)

2020 The Journal of Clinical Psychiatry
Show All
- Source
- Cite
- Save
Citations (36)
Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2).

2020 The Journal of Clinical Psychiatry
Show All
- Source
- Cite
- Save
Citations (52)
Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients with Major Depressive Disorder Who Have Active Suicide Ideation with Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II).

2020 The International Journal of Neuropsychopharmacology
Show All
- Source
- Cite
- Save
Citations (26)
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study

2019
Show All
- Source
- Cite
- Save
Citations (12)

© Copyright 2015-2020 Acemap, Inc. Shanghai Jiao Tong University.

沪ICP备18028330号